Glaucoma is a condition of the eye that damages the optic nerve. It can result in vision loss or much worst, blindness. Its pressure is a front-runner as a risk factor for this possible optic nerve damage.
What’s In The Eye?
The anterior chamber is the face in front of the eyes, and in it is a fluid that flows unceasingly in and out of it. The fluid provides nourishment to nearby tissues. It exits the chamber at an open angle located in the space where the cornea and iris converges and flows out like a drain through a spongy meshwork like structure.
In the case of open-angle glaucoma, the fluid inside the chamber is not adequately drained. Therefore, not all of the liquid makes out from the spongy meshwork. So when the fluid builds up in the chamber, it creates pressure inside the eye that possibly results in optic damage.
MIGS or minimally invasive glaucoma surgery is the latest glaucoma treatment available to the public. Apparently, in the United States, there are only two MIGS devices approved for the market and already in serious development. However, as soon as the application of the latest devices passes the proper testing and inspection, there are more devices ready for use.
Allergan – Allergan is a 6 mm XEN gel stent designed to lower eye pressure. It can be implanted through the trabeculum into the subconjunctival space of the eye through a little incision in the cornea. It is used mainly for patients with refractory glaucoma. The stent focuses on addressing refractory POAG in patients who suffer from unresponsive to maximum tolerated medical therapy. Up to date, there are more than 11,000 XEN gel stents placed all over the world.
CyPass Micro-stent – MIGS has already two approved devices in the market. There’s the Cypass, and the other one is the Glaukos or iStent. These devices reduce intraocular pressure or IOP for patients with mild to moderate POAG or open-angle glaucoma. According to experts, these devices can be easily implemented into practice by the most comprehensive ophthalmologists in the country. The invention is said to have a superior intraocular pressure lowering efficacy compared to a cataract surgery procedure.
Glaukos or iStent – It is one of the MIGS devices that are FDA approved, alongside CyPass. The iStent inject an injector has two preloaded stents. With the use of the injector, the two devices are implanted into the Schlemm’s canal to increase fluid outflow. Apart from iStent, the iStent supra also drains into the suprachoroidal space and iDose that serves as travoprost depot. It gets injected towards the sclera.
Equinox – Most glaucoma-related devices treatment methods treat glaucoma as a disease of elevated intraocular pressure; however, Equinox is different. The equinox approach to glaucoma focuses on looking at it as a disease of two pressures – by intracranial and by intraocular pressure. It labels the pressure gradient between ICP and IOP. It gently peels and eliminates eye dryness so it can replenish its nourishing extract.
InnFocus – One of the first minimally invasive devices for mild to moderate and severe POAG is the Microshunt. The device promises a sustained IOP that is below 15 mmHG. It somehow eradicates eye drop medication. As per record, it is the only device in a random controlled trial versus trabeculectomy.
There are many more risk factors that may relate to optic nerve damage and can lead to glaucoma. However, with early detection and treatment, there’s a minimized risk of having vision loss and glaucoma. There are some significant strides in the research towards treating glaucoma. Some of these innovative devices may change the way glaucoma is treated.